AbbVie Options AND Gated Bispecific Programs From DISCO

Company DISCO Pharmaceuticals; AbbVie Event Type Research and option-to-license collaboration ($40 million upfront) Modality AND-gated bispecific antibodies Asset Surfaceome-mapped target pairs (undisclosed) Target Paired tumor-surface proteins (undisclosed) Disease Area Oncology Summary DISCO Pharmaceuticals announced a research and option-to-license collaboration with AbbVie on November 19. DISCO…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *